Milestone Pharmaceuticals (NASDAQ:MIST) COO Jeffrey Edward Nelson Sells 58,007 Shares

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock in a transaction on Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24. Following the sale, the chief operating officer owned 41,993 shares in the company, valued at $97,423.76. This represents a 58.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, January 26th, Jeffrey Edward Nelson sold 12,245 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total transaction of $23,632.85.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $1.96. Milestone Pharmaceuticals Inc. has a twelve month low of $0.63 and a twelve month high of $3.06. The firm has a market cap of $165.23 million, a P/E ratio of -2.37 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Zacks Research raised shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday. Wells Fargo & Company upped their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. October Effect Ltd acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth approximately $105,000. SG Americas Securities LLC bought a new position in Milestone Pharmaceuticals in the 4th quarter worth approximately $197,000. Bay Rivers Group lifted its holdings in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares in the last quarter. Millennium Management LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter valued at $803,000. Finally, Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $1,333,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals News Roundup

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.